Invention Grant
- Patent Title: GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof
-
Application No.: US16982443Application Date: 2019-03-19
-
Publication No.: US11780916B2Publication Date: 2023-10-10
- Inventor: Xiaofeng Wang , Hua Zhang , Chenjiang Yao , Cheng Zhang , Shuqian Jing
- Applicant: Gmax Biopharm LLC
- Applicant Address: CN Zhejiang
- Assignee: Gmax Biopharm LLC
- Current Assignee: Gmax Biopharm LLC
- Current Assignee Address: CN Hangzhou
- Agency: Jones Day
- Priority: CN 1810231468.X 2018.03.20
- International Application: PCT/CN2019/078671 2019.03.19
- International Announcement: WO2019/179424A 2019.09.26
- Date entered country: 2020-09-18
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K9/00
Abstract:
Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.
Public/Granted literature
- US20210061904A1 GIPR ANTIBODY AND GLP-1 FUSION PROTEIN THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Public/Granted day:2021-03-04
Information query
